PDCD1 and neoplasm: The expression of CTLA-4, the absence of fractalkine (CX3CL1) [150], and the presence of pre-existing CD8+ T cells distinctly located at the invasive tumor margin [145] were also found to be associated with treatment responses to the PD1/PD-L1 blockage antibodies.